MMIRF(.123)MedMira Receives Russian Approval for Multiplo Test - World's First and Only Rapid 3-in-1 Test for HIV and Hepatitis
May 23, 2007 8:30:00 AM
HALIFAX, May 23 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a global market leader in premium rapid diagnostic solutions, announced today that it has received regulatory approval from the health ministry in the Russian Federation for its Multiplo(TM) Rapid HBV/HIV/HCV Antibody Test (Multiplo HBV/HIV/HCV). MedMira's Multiplo(TM) product line uses its patent-pending Mutiplo(TM) platform, and represents the newest generation of rapid diagnostic tests which can simultaneously detect multiple disease markers in minutes. Multiplo HBV/HIV/HCV detects antibodies to HIV and/or the Hepatitis B and C viruses that may be present in a blood sample, and is the first test in the Multiplo(TM) line to receive such a significant regulatory approval.
"We are now able to provide healthcare professionals worldwide with the best tool to diagnose a variety of diseases using only a single drop of blood specimen. Use of our Multiplo(TM) products offers healthcare providers with substantial time and cost savings, while enabling access to reliable, instant test results," said Hermes Chan, MedMira's President and CEO.
First introduced at XVI International AIDS Conference in Toronto, Ontario, in August 2006, the Multiplo(TM) product line includes a suite of rapid diagnostic tests for the simultaneous detection of more than one disease marker.
"MedMira's quality rapid flow though technology is like no other in the world. Its stability and flexibility puts it well ahead of the rest of the world's rapid test technologies. Testing procedures are simple, with only a single drop of specimen required and minutes later, healthcare providers and patients can receive multiple answers from a single device, allowing them make the right treatment decisions, right away," noted Mr. Chan.
Russia has one of the fastest growing HIV rates in the world, with new cases having increased 100-fold between 1997 and 2005 and representing up to 90% of all HIV cases in Eastern Europe (WHO, November 2006). According to the WHO, 85% of registered HIV-infected individuals in the Russian Federation are injection drug users; a major mode of transmission of both HBV and HCV. The prevalence of HCV infection in HIV-infected patients has been found to be particularly high in Europe, where an average of 40% of HIV-infected are co-infected with HCV. HBV is 100 times more infectious than HIV, and more than 70% of HIV-infected people have been found to have a blood marker indicating past or present HBV infection (WHO, 2006). A higher risk of death is associated with individuals infected with HIV along with both HCV and HBV, making identification of these co-infections very critical in determining the best course of treatment (www.hivinsite.ucsf.edu).
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals around the world with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union.
In January 2006, MedMira launched the Maple Biosciences division to develop and commercialize diagnostic instruments based on two revolutionary biosensor-based technology platforms. The solutions developed by Maple Biosciences will enable routine laboratory tests to be performed in a matter of minutes, increasing laboratory automation, streamlining the diagnosis of multiple conditions and diseases and positioning MedMira to be a leading participant in the emerging fields of personalized medicine and molecular diagnostics. For more information visit www.maplebio.com.
MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in China. Maples Biosciences' labs are located in Toronto, Ontario. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
Dr. James Smith
Investor Relations & Corporate Affairs